Depemokimab is a follow-up to GSK's Nucala (mepolizumab), a once-monthly IL-5 inhibitor approved for severe asthma, CRSwNP, ...
A recent trial showed that nicotinamide riboside supplementation might reduce airway inflammation in patients with COPD who ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback